Trestle Biotherapeutics · Mar 2025
Trestle announced a research collaboration with Humacyte to explore integrating Trestle’s biofabricated kidney tissues with Humacyte’s ATEV technology to generate vascularized bioengineered kidneys.
Bioengineered kidneys for patients with kidney failure
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Trestle Biotherapeutics is a preclinical biotechnology company founded in 2020 that is developing bioengineered, stem cell-derived kidney tissues intended to reduce or eliminate dialysis dependence for patients with end-stage renal disease. Public sources place it in La Jolla / San Diego, California. No public GitHub or X profile was found in the sourced materials.
Primary product
An implantable bioengineered kidney tissue / therapeutic tissue for end-stage renal disease
Founded
2020
Headquarters
9310 Athena Circle, La Jolla, CA 92037, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Regenerative medicine / kidney therapeutics
Offices
Open Positions
0 jobs at Trestle Biotherapeutics
No open positions
Check back later for new openings